2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 1, 2007, Pages 56-63

  Zhang, Xinchen ^a   Jia, Youhong ^a   Jackson, Edwin K ^a   Tofovic, Stevan P ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic renal disease; Estradiol metabolites; Metabolic syndrome; Rats

Indexed keywords

2 ETHOXYESTRADIOL; 2 METHOXYESTRADIOL; CYCLINE; DRUG VEHICLE; ESTRADIOL DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL 400; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HYPERHEMOGLOBINEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; METABOLISM; NONHUMAN; OBESITY; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT OUTCOME; URINARY EXCRETION; ZUCKER DIABETIC FATTY RAT;

AGING; ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ESTRADIOL; MALE; OBESITY; RATS; TUBULIN MODULATORS;

EID: 33846561588     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31802cb88e     Document Type: Article

References (44)

1. Linder A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
2. Coggins CH, Lewis JB, Caggiula AW, et al. Differences between men and women with chronic renal disease. Nephrol Dial Transplant. 1988;13:1430-1437.
3. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kid Dis. 2002;36:S24-30.
4. Yu HT. Progression of chronic renal failure. Arch Intern Med. 2003;163:1417-1429.
5. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kid Disease. 1995;25:515-533.
6. Neugarten J, Acharya A, Silbiger SR. Effects of gender on the progression of nondiabetic renal disease: meta-analysis. J Am Soc Nephrol. 2000;11:319-329.
7. Samak MJ, Levey S. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kid Dis. 2000:35:S117-S131.
8. Mendelson ME, Karas RH. The protective effects of estrogen on cardiovascular system. N Engl J Med. 1999;340:1801-1811.
9. Shlipak MG, Simon JA, Grady D, et al. Renal Insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38:703-711.
10. Crowley A, Menon V, Lessard D, et al. Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study). Am Heart J. 2003;146:824-831.
11. Barrett-Connor E, Giardina EG, Gitt AK, et al. Women and heart disease: The role of diabetes and hyperglycemia. Arch Intern Med. 2004;164:934-942.
12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
14. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J Pharmacol Exp Ther. 2004;308:403-409.
15. Zhu TB, Conney AH. Functional role of estrogen metabolism in target cell: review and perspectives. Carcinogenesis 1988;19:1-27.
16. Tofovic SP, Dubey R, Salah E, et al. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol. 2002;13:2737-2747.
17. Tofovic SP, Salah EM, Dubey R, et al. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol. 2005;46:25-35.
18. Tofovic SP, Mady H, Jackson EK. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic angiotensin II administration. Hypertension 2003;42:416.
19. Tofovic SP, Dubey RK, Jackson EK. 2-Hydroxyestradiol attenuates the development of obesity, metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharm Exp Ther. 2001;299:973-977.
20. Cushman M, He HM, Katzenellenbogen JA, et al. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;38:2041-2049.
21. Verdier-Pinard P, Wang Z, Mohanakrishnan K, et al. A steroid derivative with paclitaxel-like effects on tubulin polymerization. Mol Pharmacol. 2001;57:568-575.
22. Tofovic SP, Kusaka H, Kost CK, et al. Renal function and structure in diabetic, hypertensive, obese ZDF x SHHF-hybrid rats. Renal Failure. 2000;22:387-406.
23. Tofovic SP, Kost CK Jr, Jackson EK, et al. Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 [fa-fa(cp)] rats. Kidney Int. 2002;61:1433-1444.
24. Tofovic SP, Jackson EK. Animal models of the metabolic syndrome. Methods Mol Med. 2003;86:29-46.
25. Paunesku T, Mittal S, Protic M, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol. 2001;77:1007-1021.
26. Chen S, Khan ZA, Cukiemrnik M, et al. Differential activation of NF- κB and Ap-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol. 2003;284:E1089-E1097.
27. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor [gamma] agonists J Clin Invest. 2000;106:467-472.
28. Dubey RK, Gillespie DG, Wright M, et al. Antimitogenic effects of 2-methoxyestradiol, an endogenous metabolite of estradiol, are blocked by PPAR gamma antagonist: Is 2-methoxyestradiol an endogenous PPAR gamma ligand. Hypertension. 2004;44:497.
29. Guijarro C, Egido J. Transcription factor-κB (NF-κB) and renal disease. Kidney Int. 2001;59:415-424.
30. Rangan GK, Wang Y, Tay YC, et al. Inhibition of nuclear factor-kappa B activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 1999;56:118-134.
31. Lopez-Franco O, Suzuki Y, Sanjuan G, et al. Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol. 2002;161:1497-1505.
32. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003-2017.
33. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48:2229-2239.
34. Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic rats. Lab Invest. 2002;82:25-35.
35. Yang B, Lin P, Carrick KM, et al. PPAR gamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochem Biophys Res Commun. 2005;334:176-182.
36. Khamaisi M, Schrijvers BS, De Vriese AS, et al. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant. 2003;18:1427-1430.
37. De Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993-1000.
38. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51: 3090-3094.
39. Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001;7:425-429.
40. Zhao Q, Egashira K, Inoue S, et al. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation. 2002;105:1110-1115.
41. Williams B. A potential role for angiotensin II-induced vascular endothelial growth factor expression in the pathogenesis of diabetic nephropathy. Miner Electrolyte Metab. 1988;24:400-405.
42. Tamarat R, Silvestre JS, Durie M, et al. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82:747-756.
43. Pribluda VS, Gubish ER, Lavallee TM, et al. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000;19:173-179.
44. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat. 2003;6:355-361.